1. |
Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q.Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Mol Ther 2014; 22(1):169-77. doi: 10.1038/mt.2013.197.
|
2. |
Li T, Miller CH, Driggers J, Payne AB, Elliingsen D, Hooper WC.Mutation analysis of a cohort of US patients with hemophilia B. Am J Hematol 2014; 89(4):375-9. doi: 10.1002/ajh.23645.
|
3. |
Bowen DJ.Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002; 55(1):1-18. doi: 10.1136/mp. 55.1.1.
|
4. |
Seo JY, Jang MA, Kim HJ, Lee KO, Kim SH, Kim HJ.Sequence variation data of F8 and F9 genes in functionally validated control individuals: implications on the molecular diagnosis of hemophilia. Blood Res 2013; 48(3): 206-10. doi: 10.5045/br.2013.48.3.206.
|
5. |
Takahashi K, Yamanaka S.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4):663-76. doi: 10.1016/ j.cell.2006.07.024.
|
6. |
Takahashi K, Okita K, Nakagawa M, Yamanaka S.Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2(12):3081-9. doi: 10.1038/nprot.2007. 418.
|
7. |
Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 2008; 41 Suppl 1:51-6. doi: 10.1111/j.1365-2184.2008. 00493.x.
|
8. |
Iwamuro M, Komaki T, Kubota Y, Seita M, Kawamoto H, Yuasa T, et al.Comparative analysis of endoderm formation efficiency between mouse ES cells and iPS cells. Cell Transplant 2010; 19(6):831-9. doi: 10.3727/096368 910X508951.
|
9. |
Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, et al.Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009; 19(11):1233-42. doi: 10.1038/cr.2009.107.
|
10. |
Paques F, Duchateau P.Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr Gene Ther 2007; 7(1):49-66. doi: 10.2174/156652307779940216.
|
11. |
Carroll D.Genome engineering with zinc-finger nucleases. Genetics 2011; 188(4):773-82. doi: 10.1534/genetics. 111.131433.
|
12. |
Wright DA, Li T, Yang B, Spalding MH.TALEN-mediated genome editing: prospects and perspectives. Biochem J 2014; 462(1):15-24. doi: 10.1042/BJ20140295.
|
13. |
Doudna JA, Charpentier E.Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346(6213):1258096. doi: 10.1126/science. 1258096.
|
14. |
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F.Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8(11):2281-308. doi: 10.1038/nprot.2013. 143.
|
15. |
Hsu PD, Lander ES, Zhang F.Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157(6):1262-78. doi: 10.1016/j.cell.2014.05.010.
|
16. |
Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, et al.Highly efficient generation of human hepatocyte- like cells from induced pluripotent stem cells. Hepatology 2010; 51(1):297-305. doi: 10.1002/hep.23354.
|
17. |
Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J.RNA-programmed genome editing in human cells. Elife 2013; 2:e00471. doi: 10.7554/eLife.00471.
|
18. |
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337(6096):816-21. doi: 10.1126/science.1225829.
|
19. |
Cone L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al.Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339(6121):819-23. doi: 10.1126/ science.1231143.
|
20. |
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013; 339(6121):823-6. doi: 10.1126/science. 1232033.
|
21. |
Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016; 351(6271): 407-11. doi: 10.1126/science.aad5177.
|
22. |
Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, et al.Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32(6):551-3. doi: 10.1038/nbt.2884.
|
23. |
Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, et al.Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 2014; 115(5): 488-92. doi: 10.1161/CIRCRESAHA.115.304351.
|
24. |
Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, et al.The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 2014; 3:e186. doi: 10.1038/mtna.2014.38.
|
25. |
Guan Y, Ma Y, Li Q, Sun Z, Ma L, Wu L, et al.CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med 2016; 8(5):477-88. doi: 10.15252/emmm.201506039.
|
26. |
Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, et al.Seamless gene correction of b-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014; 24(9):1526-33. doi: 10.1101/gr. 173427.114.
|
27. |
Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, et al.Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cysticfibrosis patients. Cell Stem Cell 2013; 13(6):653-8. doi: 10.1016/j.stem.2013.11.002.
|
28. |
Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, et al.Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep 2015; 4(1):143-54. doi: 10.1016/j.stemcr.2014. 10.013.
|
29. |
Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA.Multiplex CRISPR/Cas9-based genome editing forcorrectionofdystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015; 6:6244. doi: 10.1038/ncomms7244.
|
30. |
Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al.High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013; 31(9):822-6. doi: 10.1038/nbt.2623.
|
31. |
Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al.DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31(9):827-32. doi: 10.1038/nbt.2647.
|
32. |
Wu XB, Andrea JK, Philip AS.Target specificity of the CRISPR-Cas9 system. Quant Biol 2014, 2(2):59-70. doi: 10.1007/s40484-014-0030-x.
|
33. |
Ashrani AA, Reding MT, Shet A, Osip J, Humar A, Lake JR, et al.Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor Ⅷ inhibitor. Haemophilia 2004; 10(6):735-7. doi: 10.1111/j.1365-2516. 2004.01030.x.
|
34. |
Wilde J, Teixeira P, Bramhall SR, Gunson B, Mutimer D, Mirza DF.Liver transplantation in haemophilia. Br J Haematol 2002; 117(4):952-6. doi: 10.1046/j.1365-2141. 2002.03528.x.
|
35. |
Gordon FH, Mistry PK, Sabin CA, Lee CA.Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42(5):744-9. doi: 10.1136/gut.42.5.744.
|
36. |
Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371(21):1994-2004. doi: 10.1056/NEJMoa 1407309.
|
37. |
Sharma A, Easow MM, Sriganesh V, Neely JA, Kalipatnapu S. Gene therapy for haemophilia. Cochrane Database Syst Rev 2014; 11:CD010822. doi: 10.1002/ 14651858.CD010822.pub2.
|